Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare
products, today announced that its Surgical Devices business unit has
introduced the VascuSeal™ Vascular Sealant
System throughout Europe and in select Middle East markets. VascuSeal™ offers surgeons a unique advanced hydrogel that provides an immediate
blood-tight seal that is effective intraoperatively and throughout the
critical healing period. VascuSeal™, which is
CE-Marked, is intended for use as a surgical sealant during arterial and
venous reconstructions to seal suture lines.
Unlike a hemostatic agent, a vascular sealant can seal blood leaks and
does not depend on either the time for the blood to clot or the strength
of the blood clot to perform successfully. The VascuSeal™ Sealant System offers surgeons a valuable tool to reduce bleeding from
the suture line in vascular bypass procedures, and reduces
post-operative complications associated with suture line bleeding.
The VascuSeal™ sealant technology is a
patented synthetic, absorbable hydrogel delivered by a dual syringe
applicator. The device can be stored at room temperature and prepared in
less than two minutes. VascuSeal™ sealant
polymerizes within seconds when sprayed on the suture line and is blue
in color which provides the vascular surgeon visualization of coverage
and thickness of the material upon application. Postoperatively
VascuSeal™sealant continues to seal the
suture line as healing progresses under the gel. After several days, the
hydrogel breaks down into water-soluble molecules that are absorbed and
cleared through the kidneys.
"The VascuSeal™ Vascular Sealant System represents another innovative product in the
BioSurgery marketplace," said Scott Flora
President, Surgical Devices, Covidien. "We
expect VascuSeal™ to be well-received by
surgeons looking to improve patient outcomes, save time and reduce blood
loss during surgical procedures," added Flora.
ABOUT COVIDIEN
Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers
value through clinical leadership and excellence. Covidien manufactures
distributes and services a diverse range of industry-leading product
lines in four segments: Medical Devices, Imaging Solutions
Pharmaceutical Products and Medical Supplies. With 2007 revenue of
nearly $9 billion, Covidien has more than 42,000 employees worldwide in
57 countries, and its products are sold in over 130 countries. Please
visit www.covidien.com to learn
more about our business.
